

Special Issue

Bone Health Management in the Continuum of Prostate Cancer Disease

Message from the Guest Editor

Bone health impairment is a frequent detrimental consequence of the high bone tropism of prostate cancer (PCa) cells. It is further worsened by the administration of androgen-deprivation therapy (ADT, the current standard of care in the management of advanced PCa), through a rapid and dramatic increase in bone turnover and body mass changes. To address this urgent unmet need, following a thorough discussion of available data and sharing of their clinical practice experience, a panel of international experts in the field of bone health and metabolism will formulate a collection of advice for optimizing the monitoring and treatment of bone health in men undergoing ADT during all phases of the disease. This Special Issue will review current evidence regarding the effects of ADT on bone health, of novel hormone therapies (which improve progression delay, pain control, and QoL while consistently carrying the risk of non-pathological fractures in both non-metastatic and metastatic PCa), and of bone turnover inhibitors (BTTs, whose use is frequently suboptimal). Finally, expert opinion on optimizing bone health preservation will be given.

Guest Editor

Prof. Dr. Santini Daniele

Department of Medical Oncology, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 200, 00128 Rome, Italy

Deadline for manuscript submissions

closed (30 April 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/39291

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)